Tizanidine Hydrochloride Capsule
Product Images NDC 62332-493

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 62332-493). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tizanidine 2 mg

Label for Tizanidine Hydrochloride capsules, 2 mg strength, supplied in a 30-capsule container. The label includes dosage information, storage instructions, barcode, and manufacturer details for Alembic Pharmaceuticals, Inc. It also has a warning that these capsules are not interchangeable with tizanidine tablets.*

FDA Label Image

Tizanidine 4 mg

Label for Tizanidine Hydrochloride Capsules, 4 mg strength in a bottle containing 30 capsules. The label includes the NDC 62332-492-30 and is manufactured by Alembic Pharmaceuticals Limited in India and Alembic Pharmaceuticals, Inc. in the USA. It states the product is prescription only, with storage instructions and a warning not to interchange with certain other medications.*

FDA Label Image

Tizanidine 6 mg

Label for Tizanidine Hydrochloride Capsules 6 mg by Alembic Pharmaceuticals Inc. The label indicates a 30-capsule package and includes a note that each capsule contains 6.87 mg of tizanidine hydrochloride, USP equivalent to 6 mg tizanidine base. It features storage instructions, a warning not to interchange with tizanidine or Zanaflex tablets, manufacturer details, and barcode.*

FDA Label Image

Tizanidine-figure-1.jpg (Tizanidine Figure 1)

A line graph depicting the plasma concentration of Tizanidine over time, measured in ng/mL, across 24 hours after dosing. It compares the pharmacokinetics of 2 x 4 mg Tizanidine tablets and capsules taken with and without food. The y-axis shows plasma concentration from 0 to 6 ng/mL, and the x-axis represents hours from dosing, ranging from 0 to 24 hours.*

FDA Label Image

Tizanidine-figure-2.jpg (Tizanidine Figure 2)

A line graph illustrating the improvement in Ashworth Score over 6 hours post-dose for 16 mg tizanidine, 8 mg tizanidine, and placebo. The vertical axis shows improvement scores ranging from 1 to -5, and the horizontal axis shows time in hours post-dose from 0 to 6. The graph includes error bars and demonstrates changes in muscle spasticity assessments at specified times for each treatment group.*

FDA Label Image

Tizanidine-figure-3.jpg (Tizanidine Figure 3)

A line chart comparing improvement in Ashworth Score over three study time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). The graph displays data for two groups: tizanidine (mean dose 28.8 mg) showing greater improvement (negative score) and placebo showing less improvement, with error bars indicating variability.*

FDA Label Image

Tizanidine-str.jpg (Tizanidine Str)

Chemical structure of Tizanidine Hydrochloride showing its molecular components and arrangement, including a chlorinated aromatic ring and thiazole ring system with a hydrochloride moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.